Never mana_老虎社区_美港股上老虎

2021-10-04

Never manage to get IPO before.. Sigh..

US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国 IPO 周即将到来：新发行人在健身主导的第五 IPO 周大汗淋漓</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":867479904,"tweetId":"867479904","gmtCreate":1633311153667,"gmtModify":1633311173565,"author":{"id":4089081450453300,"idStr":"4089081450453300","authorId":4089081450453300,"authorIdStr":"4089081450453300","name":"JokerForever","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Never manage to get IPO before.. Sigh..&nbsp;</body></html>","htmlText":"<html><head></head><body>Never manage to get IPO before.. Sigh..&nbsp;</body></html>","text":"Never manage to get IPO before.. Sigh..","highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/867479904","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohunote.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国 IPO 周即将到来：新发行人在健身主导的第五 IPO 周大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在 10 月份的第一个完整星期，五次 IPO 预计将筹集 18 亿美元，由两家健身公司牵头。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH) 计划以 41 亿美元的市值筹集 9.01 亿美元。Life Time于2015年私有化，在美国29个州和加拿大的一个省运营着150多个“中心”，截至21年7月31日，为近140万个人会员提供服务。虽然该公司受到疫情的沉重打击，但此后运营已显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT) 计划以 64 亿美元的市值筹集 6 亿美元。iFIT是美国排名第一的大型健身器材供应商，销售的品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速且不盈利，为120多个国家的610多万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组平台等复合（ISO）计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis相信其平台是第一个采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。该公司的平台快速增长且高度无利可图，自2018年6月商业推出以来，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX) 计划以 5.93 亿美元的市值筹集 1.25 亿美元。Theseus 的主要候选药物是胃肠道间质瘤 (GIST) KIT 激酶所有主要激活/抗性突变类别的泛变体抑制剂。该公司最近提交了高级 GIST 的 IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动 1/2 期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发商扣带（CING）计划以2.25亿美元的市值筹集5000万美元。它的两个候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTx-1301的1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国 IPO 周即将到来：新发行人在健身主导的第五 IPO 周大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国 IPO 周即将到来：新发行人在健身主导的第五 IPO 周大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在 10 月份的第一个完整星期，五次 IPO 预计将筹集 18 亿美元，由两家健身公司牵头。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH) 计划以 41 亿美元的市值筹集 9.01 亿美元。Life Time于2015年私有化，在美国29个州和加拿大的一个省运营着150多个“中心”，截至21年7月31日，为近140万个人会员提供服务。虽然该公司受到疫情的沉重打击，但此后运营已显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT) 计划以 64 亿美元的市值筹集 6 亿美元。iFIT是美国排名第一的大型健身器材供应商，销售的品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速且不盈利，为120多个国家的610多万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组平台等复合（ISO）计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis相信其平台是第一个采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。该公司的平台快速增长且高度无利可图，自2018年6月商业推出以来，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX) 计划以 5.93 亿美元的市值筹集 1.25 亿美元。Theseus 的主要候选药物是胃肠道间质瘤 (GIST) KIT 激酶所有主要激活/抗性突变类别的泛变体抑制剂。该公司最近提交了高级 GIST 的 IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动 1/2 期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发商扣带（CING）计划以2.25亿美元的市值筹集5000万美元。它的两个候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTx-1301的1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LTH":"Life Time Group Holdings, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"THRX":0.9,"IFIT":0.9,"ISO":0.9,"CING":0.9,"LTH":0.9}},"isVote":1,"tweetType":1,"viewCount":767,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":33,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/867479904"}